
    
      The objective of this NIS is to measure changes in health status including functional status
      using CCQ scores in COPD patients receiving treatment with Spiolto® Respimat® according to
      label after approximately 6 weeks in routine clinical practice.

      In visit 1, patient data on demographics, smoking status, medical history, breathlessness,
      general condition, health and functional status and adverse drug reactions will be collected.
      In visit 2, after approximately 6 weeks, data on smoking status, concomitant diseases and
      medication, general condition, health and functional status and adverse drug reactions will
      be collected; additionally data on patient satisfaction, continuation or discontinuation of
      treatment and the reason in case of discontinuation.
    
  